Holen Sie sich die Stockscreener-App
3.39
2.31%
-0.08
Vorhandelsmarkt:
3.33
-0.06
-1.77%
Schlusskurs vom Vortag:
$3.47
Offen:
$3.49
24-Stunden-Volumen:
2.69M
Relative Volume:
1.10
Marktkapitalisierung:
$612.29M
Einnahmen:
$4.63M
Nettoeinkommen (Verlust:
$-201.14M
KGV:
-2.4671
EPS:
-1.3741
Netto-Cashflow:
$-167.10M
1W Leistung:
-8.13%
1M Leistung:
+2.11%
6M Leistung:
-22.95%
1J Leistung:
+115.92%
1-Tages-Spanne:
$3.28
$3.56
1-Wochen-Bereich:
$3.28
$3.69
52-Wochen-Spanne:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Firmenname
Prime Medicine Inc
Sektor
Branche
Telefon
617-465-0013
Adresse
60 FIRST ST., CAMBRIDGE
Compare PRME vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.39 | 612.29M | 4.63M | -201.14M | -167.10M | -1.3741 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-04-08 | Eingeleitet | TD Cowen | Buy |
| 2024-04-03 | Eingeleitet | Wedbush | Outperform |
| 2024-01-16 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Eingeleitet | Citigroup | Neutral |
| 2023-10-09 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-07-31 | Eingeleitet | Guggenheim | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2022-11-14 | Eingeleitet | Goldman | Neutral |
| 2022-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2022-11-14 | Eingeleitet | Jefferies | Buy |
| 2022-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prime Medicine Inc Aktie (PRME) Neueste Nachrichten
PRME SEC FilingsPrime Medicine 10-K, 10-Q, 8-K Forms - Stock Titan
Prime Medicine (NASDAQ:PRME) Upgraded to Sell at Wall Street Zen - MarketBeat
PRME Stock Price, Quote & Chart | PRIME MEDICINE INC (NASDAQ:PRME) - ChartMill
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates - MSN
Prime Medicine (NASDAQ:PRME) Stock Rating Lowered by Wall Street Zen - MarketBeat
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates - MSN
Prime Medicine, Inc. (NASDAQ:PRME) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
PRME Price Today: Prime Medicine, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Prime Medicine, Inc. ($PRME) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Prime Medicine, Inc. SEC Filing - Stock Titan
Prime Medicine (NASDAQ: PRME) details 2026 meeting, board elections and pay - Stock Titan
PRME (Prime Medicine Inc.) posts 55 percent year over year Q4 2025 revenue growth, shares rise modestly. - Xã Thanh Hà
Prime Medicine slides after pricing $125.4M stock offering - MSN
HC Wainwright & Co. Downgrades Prime Medicine (PRME) - MSN
Prime Medicine (PRME) Appoints Svetlana Makhni as Chief Financial Officer - Yahoo Finance
Bristol Myers Squibb (BMY) – Gene Editing Partner Prime Medicine (PRME) Announces Strategic CFO Hire, Bullish Analyst InitiationRisk Report - Cổng thông tin điện tử tỉnh Lào Cai
Prime Medicine (PRME) Financials 2026Income Statement and Balance Sheet - MarketBeat
Wall Street Zen Upgrades Prime Medicine (NASDAQ:PRME) to Sell - MarketBeat
Sumitomo Mitsui Trust Group Inc. Sells 384,418 Shares of Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine (PRME) awards CFO 800,000 stock options at $3.67 - Stock Titan
Prime Medicine (PRME) CFO Makhni Svetlana Ni submits initial Form 3 - Stock Titan
Prime Medicine names Svetlana Makhni as chief financial officer By Investing.com - Investing.com Australia
Prime Medicine appoints Svetlana Makhni as CFO By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Prime Medicine names Svetlana Makhni as chief financial officer - Investing.com
Prime Medicine, Inc. Appoints Svetlana Makhni as Chief Financial Officer - marketscreener.com
Prime Medicine Appoints Svetlana Makhni as New CFO - TipRanks
Prime Medicine appoints Svetlana Makhni as chief financial officer By Investing.com - Investing.com Australia
Prime Medicine appoints Svetlana Makhni as chief financial officer - Investing.com
Prime Medicine appoints Svetlana Makhni as CFO - Investing.com
CFO package at Prime Medicine (NASDAQ: PRME) details pay, options and severance - Stock Titan
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer - The Manila Times
Prime Medicine hires CFO as it prepares for two clinic entries - Stock Titan
Short Covering: Whats the fair value of Prime Medicine Inc stockTrade Performance Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Prime Medicine (NASDAQ:PRME) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Top Prime Medicine (PRME) Competitors 2026 - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 6.4%Here's What Happened - MarketBeat
Is Prime Medicine (PRME) Stock trading below intrinsic value | Price at $3.29, Down 6.41%Trending Picks - Cổng thông tin điện tử Tỉnh Sơn La
Prime Medicine slips after Q4 updates - MSN
PRME PE Ratio & Valuation, Is PRME Overvalued - Intellectia AI
Stock Market Recap: Whats the fair value of Prime Medicine Inc stock2026 WrapUp & Community Trade Idea Sharing - baoquankhu1.vn
Finanzdaten der Prime Medicine Inc-Aktie (PRME)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):